Faculty Disclosures
| Shamikha cheema, MBBS |
Dr. cheema has nothing to disclose. |
| Ning Zhong, MD |
Dr. Zhong has nothing to disclose. |
| Justin Liao |
Mr. Liao has nothing to disclose. |
| Peng Hu |
Mr. Hu has nothing to disclose. |
| Diego A. Pizzagalli, PhD |
Prof. Pizzagalli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Prof. Pizzagalli has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alkermes. Prof. Pizzagalli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead Pharmaceuticals. Prof. Pizzagalli has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neumora. Prof. Pizzagalli has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boehringer. Prof. Pizzagalli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Circular Genomics. Prof. Pizzagalli has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Compass Pathway. Prof. Pizzagalli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Engrail. Prof. Pizzagalli has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine . Prof. Pizzagalli has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neuroscience Software. Prof. Pizzagalli has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Psychonomic Society. Prof. Pizzagalli has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Psychological Association. Prof. Pizzagalli has stock in Ceretype Neuromedicine. Prof. Pizzagalli has stock in Compass Pathway. Prof. Pizzagalli has stock in Engrail Therapeutics. Prof. Pizzagalli has stock in Neumora Therapeutics. Prof. Pizzagalli has stock in Neuroscience Software. |
| Imran H. Quraishi, MD, PhD |
The institution of Dr. Quraishi has received research support from NeuroPace. The institution of Dr. Quraishi has received research support from Biogen. The institution of Dr. Quraishi has received research support from Praxis Precision Medicines. |
| Sandeep Kumar, MBBS |
Dr. Kumar has nothing to disclose. |
| Martha Morrell, MD, FAAN |
Dr. Morrell has received personal compensation for serving as an employee of NeuroPace. Dr. Morrell has stock in NeuroPace. The institution of Dr. Morrell has received research support from National Institutes of Health. |
| Dorris Luong, NP |
Ms. Luong has nothing to disclose. |
| yaato li |
Dr. li has nothing to disclose. |
| Giridhar P. Kalamangalam, MD, PhD |
Dr. Kalamangalam has nothing to disclose. |
| Kurt Y. Qing, MD, PhD |
Dr. Qing has nothing to disclose. |
| Yixin Jia |
Miss Jia has received personal compensation for serving as an employee of Monell Chemical Senses Center. |
| Catherine Schevon, MD |
The institution of Dr. Schevon has received research support from NIH/NINDS. Dr. Schevon has received personal compensation in the range of $500-$4,999 for serving as a Study Section Regular Member with NIH. |
| Juncheng Li |
No disclosure on file
|
| Abby Brand |
The institution of Miss Brand has received research support from NIH. |
| Brian Jung, MD |
Dr. Jung has nothing to disclose. |
| Doris Deng, MD |
Dr. Deng has nothing to disclose. |
| Molly Murch |
Ms. Murch has nothing to disclose. |
| Nathaniel Rolfe, BA |
Mr. Rolfe has nothing to disclose. |
| Huitong Ding, PhD |
Dr. Ding has nothing to disclose. |
| Guy M. McKhann, MD |
No disclosure on file
|
| Zhen Hong |
Prof. Hong has nothing to disclose. |
| Naoum P. Issa, MD, PhD |
Dr. Issa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CVS/Caremark. The institution of Dr. Issa has received research support from NIH. Dr. Issa has received intellectual property interests from a discovery or technology relating to health care. Dr. Issa has a non-compensated relationship as a Scientific advisory board member with Theta Neurotech that is relevant to AAN interests or activities. |
| Arnold Gammaitoni, PharmD |
Dr. Gammaitoni has received personal compensation for serving as an employee of Zogenix Inc.. Dr. Gammaitoni has received stock or an ownership interest from Zogenix Inc.. |
| Silvana Frizzo, MD |
Dr. Frizzo has received personal compensation for serving as an employee of Praxis Precision Medicines. Dr. Frizzo has stock in Praxis Precision Medicines. |
| Daniel Friedman, MD, FAAN |
The institution of Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Study Consortium (non-profit). Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Meili Technology. Dr. Friedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Friedman has stock in Neuroview Technology. The institution of Dr. Friedman has received research support from NIH. The institution of Dr. Friedman has received research support from CDC. The institution of Dr. Friedman has received research support from Epitel. The institution of Dr. Friedman has received research support from Neuropace. The institution of Dr. Friedman has received research support from Rapport Therapeutics. Dr. Friedman has received intellectual property interests from a discovery or technology relating to health care. Dr. Friedman has received intellectual property interests from a discovery or technology relating to health care. Dr. Friedman has received publishing royalties from a publication relating to health care. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Speaker Honorarium with SK Life Sciences. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Speaker Honorarium with AAN. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Travel Reimbursement with Epilepsy Foundation of America. |
| Patrick Landazuri, MD, FAAN |
Dr. Landazuri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuropace. Dr. Landazuri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuropace. Dr. Landazuri has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Federal Public Defender - District of Kansas. Dr. Landazuri has received publishing royalties from a publication relating to health care. |
| Dharit Patel, MD |
Mr. Patel has received personal compensation for serving as an employee of Praxis Precision Medicines, Inc.. |
| aditya duhan, MD |
Dr. duhan has nothing to disclose. |
| Medha Menon, MBBS |
Dr. Menon has nothing to disclose. |
| Nancy Wyant |
Mrs. Wyant has nothing to disclose. |
| Osama M. Younis, MD |
Dr. Younis has nothing to disclose. |
| Henry Jacotin |
Henry Jacotin has received personal compensation for serving as an employee of Praxis Precision Medicines. Henry Jacotin has stock in Praxis Precision Medicines. Henry Jacotin has stock in Clover Health. Henry Jacotin has stock in Certara. Henry Jacotin has stock in Takeda. Henry Jacotin has received personal compensation in the range of $500,000-$999,999 for serving as a VP Clinical Development and Pharmacovigilance with Praxis Precision Medicines. |
| Heyagn Sun |
Dr. Sun has nothing to disclose. |
| Subeikshanan Venkatesan, MBBS |
Dr. Venkatesan has nothing to disclose. |
| Marcio Souza |
Marcio Souza has received personal compensation for serving as an employee of Praxis Precision Medicines. |
| James W. Wheless, MD, FAAP, FACP, FAAN, FAES, FCNS, FAAN |
Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Azurity. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for LivaNova. Dr. Wheless has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelius. |
| william motel, PhD |
Dr. motel has nothing to disclose. |
| Robert Horton |
Mr. Horton has received personal compensation for serving as an employee of Praxis Precision Medicines. Mr. Horton has stock in Praxis Precision Medicines. |
| Brett Youngerman, MD, MS |
Brett Youngerman, MD, MS has nothing to disclose. |
| Jeffrey N. Bruce, MD |
The institution of Dr. Bruce has received research support from NIH. Dr. Bruce has received intellectual property interests from a discovery or technology relating to health care. |
| Brian J. Gill, MD |
Dr. Gill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BrainLab. |
| Ingo Borggraefe, MD |
Prof. Borggraefe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Praxis. Prof. Borggraefe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke. Prof. Borggraefe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz. Prof. Borggraefe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Desitin. Prof. Borggraefe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Prof. Borggraefe has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Thieme. |
| Bradley Galer, MD |
No disclosure on file
|
| FNU VAIBHAV |
Mr. VAIBHAV has nothing to disclose. |
| Neal Nolan, MD |
Dr. Nolan has received personal compensation for serving as an employee of Vertex Pharmaceuticals and Rapport Therapeutics. Dr. Nolan has stock in Rapport Therapeutics. |
| David King-Stephens, MD |
Dr. King-Stephens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. King-Stephens has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. King-Stephens has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. |
| Matias Wagner, MD |
Dr. Wagner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke Therapeutics. Dr. Wagner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharming Group. The institution of Dr. Wagner has received research support from Novartis. Dr. Wagner has received personal compensation in the range of $500-$4,999 for serving as a speaker with Jazz Pharmaceutics. Dr. Wagner has received personal compensation in the range of $0-$499 for serving as a speaker with UCB. Dr. Wagner has received personal compensation in the range of $0-$499 for serving as a speaker with Desitin. |
| Jacqueline French, MD, FAAN |
Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Epilepsy Foundation. The institution of Dr. French has received research support from Epilepsy Study Consortium/ Epilepsy Foundation (Funded by UCB). The institution of Dr. French has received research support from GW/One8 Foundation/FACES. The institution of Dr. French has received research support from NINDS. The institution of Dr. French has received research support from Xenon. The institution of Dr. French has received research support from Cerevel. The institution of Dr. French has received research support from FACES. The institution of Dr. French has received research support from UCB. The institution of Dr. French has received research support from Epilepsy Study Consortium. The institution of Dr. French has received research support from UCB. The institution of Dr. French has received research support from Praxis. Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Medical/Innovation Officer with Epilepsy Foundation. Dr. French has a non-compensated relationship as a Consultant with Acadia Pharmaceuticals Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Access Industries that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Acuta Capital Partners LLC that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with AFASCI Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Agrithera, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Alkermes that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Angelini Pharma S.p.A. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Autifony Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Axonis Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bain Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Beacon Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Biogen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Biohaven Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Bloom Science, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bright Minds Biosciences, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Capsidia Biotherapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Cerebral Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerecin, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Cerevel that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, SAB with Cognizance Biomarkers that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ceribell that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cowen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Crossject that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board with EcoR1 Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EG 427 that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant, Advisory Board with Eisai that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Encoded Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant/Advisory Board with Engrail that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epitel, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EpiMinder that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Grin Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Harmony that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board with Ionis Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with iQure Pharma, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with IQVIA that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Janssen Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Jazz Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Leal Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, with Livanova that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with London Research & Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Longboard Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Maplight Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Marinus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Medscape/Web MD that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Modulight Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Montara Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Mosaica Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neumarker that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Neumirna Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neurelis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board with Neurocrine that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neuropace that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NeuroPro Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Neuroventis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Neurona Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board with Neuvarti that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Noema that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ono Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board with Otsuka that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board with Ovid Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Praxis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with PureTech LYT Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with QurAlis Corp that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Rapport Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Receptor Holdings, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Rivervest Venture Partners that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Sage Therapeutics, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with SK Life Science that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Stoke that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Stream Neuroscience that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Supernus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Takeda that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Taysha Gene Therapies that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with UCB, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with uniQure that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Ventus Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Vida Ventures Management that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Xenon Pharmaceuticals that is relevant to AAN interests or activities. |
| Weifang Gao |
Dr. Gao has nothing to disclose. |
| Melodie R. Winawer, MD, MS |
Dr. Winawer has nothing to disclose. |
| Julia Furnari |
No disclosure on file
|
| Kai Qiao |
Dr. Qiao has nothing to disclose. |
| Chris Troedson, MBBS, FRACP |
Dr. Troedson has nothing to disclose. |
| Huaizhi Ge |
Mr. Ge has nothing to disclose. |
| Peimin Yu |
Dr. Yu has nothing to disclose. |
| Osama Al-Dalahmah |
No disclosure on file
|
| Victoria Ho, MD, PhD |
The institution of Dr. Ho has received research support from NIH. |
| Melanie Lucas, PhD |
Dr. Lucas has nothing to disclose. |
| Divya Yadav, MD |
Dr. Yadav has nothing to disclose. |
| Vikram Rao, MD |
Dr. Rao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precisis GmbH. Dr. Rao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for iVEAcare. Dr. Rao has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace, Inc.. Dr. Rao has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Rao has stock in Novela Neurotechnologies. Dr. Rao has stock in EnlitenAI. Dr. Rao has stock in Doximity, Inc. Dr. Rao has stock in Theta Neurotech. Dr. Rao has stock in Encephalogix. |
| Haneen Alsha'ar |
Ms. Alsha'ar has nothing to disclose. |
| William Burns, MD |
Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi Therapeutics. |
| Mona Sazgar, MD |
Dr. Sazgar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Sazgar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon. Dr. Sazgar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Sazgar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurelis. Dr. Sazgar has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Sazgar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Lifesciences. The institution of Dr. Sazgar has received research support from UCB. Dr. Sazgar has received publishing royalties from a publication relating to health care. |
| Chen WANG, PhD |
Dr. WANG has nothing to disclose. |
| Sebastian Hanna, MD |
Mr. Hanna has nothing to disclose. |
| Vipul Kaliraman, MBBS |
Dr. Kaliraman has nothing to disclose. |
| Thomas Li, PhD |
Dr. Li has nothing to disclose. |
| Ke Xu |
Miss Xu has nothing to disclose. |
| Ahmad Saeed, MD |
Mr. Saeed has nothing to disclose. |
| Guoxing Zhu, MD |
Prof. Zhu has nothing to disclose. |
| Anadi Mahajan, MPharm |
Mr. Mahajan has nothing to disclose. |
| Majed S. Hbahbih, MD |
Dr. Hbahbih has nothing to disclose. |
| Steven Petrou, FAHMS |
Dr. Petrou has received personal compensation for serving as an employee of Praxis Precision Medicines. Dr. Petrou has stock in Praxis Precision Medicines. The institution of Dr. Petrou has received research support from Praxis Precision Medicines. Dr. Petrou has received intellectual property interests from a discovery or technology relating to health care. |
| Eman M. Hassan, MD |
Dr. Hassan has nothing to disclose. |
| Nan Lin, MD |
Dr. Lin has nothing to disclose. |
| Clara Stucke, Technician |
Miss Stucke has nothing to disclose. |
| Sumeet Vadera, MD |
Dr. Vadera has nothing to disclose. |
| Katherine Howell, MBBS, PhD, FRACP |
The institution of Dr. Howell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. The institution of Dr. Howell has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Howell has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SCN2A Australia. The institution of Dr. Howell has received research support from UCB. Dr. Howell has a non-compensated relationship as a Prior research support, ongoing collaboration with Praxis Precision Medicines that is relevant to AAN interests or activities. |
| Neil Feldstein, MD |
No disclosure on file
|
| Zi Liang, Jr., MD, no |
Mr. Liang has nothing to disclose. |
| Brian Spar |
Mr. Spar has received personal compensation for serving as an employee of Praxis Precision Medicines. |
| Shahnawaz Karim, MBBS |
Dr. Karim has received personal compensation for serving as an employee of TPMG. |
| Ankit -, MBBS |
Dr. - has nothing to disclose. |
| Peter Canoll, MD, PhD |
The institution of Dr. Canoll has received research support from NIH. |
| Lilit Mnatsakanyan, MD |
Dr. Mnatsakanyan has nothing to disclose. |
| Beth Lopour |
The institution of Dr. Lopour has received research support from NIH. The institution of Dr. Lopour has received research support from Department of Defense. The institution of Dr. Lopour has received research support from John C. Hench Foundation. Dr. Lopour has received personal compensation in the range of $500-$4,999 for serving as a grant reviewer with NIH. |
| William Motley, MD |
Dr. Motley has received personal compensation for serving as an employee of Rapport Therapeutics. An immediate family member of Dr. Motley has received personal compensation for serving as an employee of Eli Lilly & Co. |
| Ashwin Viswanathan, BA |
Mr. Viswanathan has nothing to disclose. |
| Ming Lu |
Ming Lu has received personal compensation for serving as an employee of Eli Lilly and Company. Ming Lu has stock in Eli Lilly and Company. |
| Kathryn A. Davis, MD |
Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharmaceuticals/Jazz Pharmaceuticals. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UNEEG. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Davis has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Pfizer. The institution of Dr. Davis has received research support from Eisai. The institution of Dr. Davis has received research support from Liminal. Dr. Davis has received publishing royalties from a publication relating to health care. |
| Hazim M. Aldweik, MD |
Dr. Aldweik has nothing to disclose. |